Recurrent GI bleeding and surgery following the initial response to imatinib therapy in GIST of the stomach.
El Hajj
Ihab I
II
Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Chehal
Aref
A
El Saghir
Nagi S
NS
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002455:Cell Division; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology*; D046152:Gastrointestinal Stromal Tumors / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D006801:Humans; D000068877:Imatinib Mesylate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000150:complications*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate